AGR, LMR and SIRI are the optimal combinations for risk stratification in advanced patients with non-small cell lung cancer following immune checkpoint blockers

This publication has 41 references indexed in Scilit:

• Antioxidant dipeptide, cyclo (Phe-Phe), protects against bone dysplasia by suppression of phospholipid peroxidation
  Cell Investigation, 2025
• RNA-binding protein Roq modulates the Drosophila STING antiviral immune response
  Cell Investigation, 2025
• Increased co-expression of CTLA4/LAG3 predicted adverse clinical outcomes in patients with T-cell malignancies
  Cell Investigation, 2025
• NRI and SIRI are the optimal combinations for prognostic risk stratification in patients with non-small cell lung cancer after EGFR-TKI therapy
  Clinical and Translational Oncology, 2024
• Systemic inflammation response index (SIRI) as a predictive factor for overall survival in advanced soft tissue sarcoma treated with eribulin
  Journal of Orthopaedic Science, 2022
• Systemic inflammation markers and cancer incidence in the UK Biobank
  European Journal of Epidemiology, 2021
• Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
  Mayo Clinic Proceedings, 2019
• Pretreatment albumin to globulin ratio can serve as a prognostic marker in human cancers: a meta-analysis
  Clinica Chimica Acta, 2018
• A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy
  Cancer, 2016
• Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies
  The Lancet, 2008